FSHR gene polymorphisms influence bone mineral density and bone turnover in postmenopausal women

European Journal of Endocrinology

Volumn 163, Issue 1, 2010, Pages 165-172

  Rendina, Domenico ^a   Gianfrancesco, Fernando ^b   De Filippo, Gianpaolo ^c   Merlotti, Daniela ^d   Esposito, Teresa ^b   Mingione, Alessandra ^b   Nuti, Ranuccio ^d   Strazzullo, Pasquale ^a   Mossetti, Giuseppe ^a   Gennari, Luigi ^d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^c G RUMMO HOSPITAL   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CARBOXY TERMINAL TELOPEPTIDE; FOLLITROPIN RECEPTOR;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE TURNOVER; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ABSORPTIOMETRY, PHOTON; AGED; BONE AND BONES; BONE DENSITY; BONE DISEASES, METABOLIC; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POLYMORPHISM, GENETIC; POSTMENOPAUSE; RECEPTORS, FSH;

EID: 77954125660     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0043     Document Type: Article

References (41)

1. Karsenty G. The complexities of skeletal biology. Nature 2003 423 316-318.
2. Boyle WJ, Simonet WS & Lacey DL. Osteoclast differentiation and activation. Nature 2003 423 337-342.
3. Harada S & Rodan GA. Control of osteoblast function and regulation of bone mass. Nature 2003 423 349-355. (Pubitemid 40852710)
4. Lorenzo J, Horowitz M & Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocrine Reviews 2008 29 403-440. (Pubitemid 351831507)
5. Jimi E & Ghosh S. Role of nuclear factor-kappaB in the immune system and bone. Immunological Reviews 2005 208 80-87. (Pubitemid 41746386)
6. Blair HC & Zaidi M. Osteoclastic differentiation and function regulated by old and new pathways. Reviews in Endocrine & Metabolic Disorders 2006 7 23-32.
7. Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF & Zaidi M. TSH is a negative regulator of skeletal remodeling. Cell 2003 115 151-162.
8. Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachristou DJ, Zaidi S, Zhu LL, Yaroslavskiy BB, Zhou H, Zallone A, Sairam MR, Kumar TR, Bo W, Braun J, Cardoso-Landa L, Schaffler MB, Moonga BS, Blair HC & Zaidi M. FSH directly regulates bone mass. Cell 2006 125 247-260.
9. Zaidi M, Blair HC, Iqbal J, Zhu LL, Kumar TR, Zallone A & Sun L. Proresorptive actions of FSH and bone loss. Annals of the New York Academy of Sciences 2007 1116 376-382.
10. Dierich A, Sairam MR, Monaco L, Fimia GM, Gansmuller A, LeMeur M & Sassone-Corsi P. Impairing follicle-stimulating hormone (FSH) signaling in vivo: targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. PNAS 1998 95 13612-13617.
11. Danilovich N, Babu PS, Xing W, Gerdes M, Krishnamurthy H & Sairam MR. Estrogen deficiency, obesity, and skeletal abnormalities in follicle-stimulating hormone receptor knockout (FORKO) female mice. Endocrinology 2000 141 4295-4308.
12. Kumar TR. FSHbeta knockout mouse model: a decade ago and into the future. Endocrine 2009 36 1-5.
13. Sowers MR, Greendale GA, Bondarenko I, Finkelstein JS, Cauley JA, Neer RM & Ettinger B. Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN. Osteoporosis International 2003 14 191-197.
14. Sowers MR, Jannausch M, McConnell D, Little R, Greendale GA, Finkelstein JS, Neer RM, Johnston J & Ettinger B. Hormone predictors of bone mineral density changes during the menopausal transition. Journal of Clinical Endocrinology and Metabolism 2006 91 1261-1267.
15. Devleta B, Adem B & Senada S. Hypergonadotropic amenorrhea and bone density: new approach to an old problem. Journal of Bone and Mineral Metabolism 2004 22 360-364.
16. Iqbal J, Sun L, Kumar TR, Blair HC & Zaidi M. Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. PNAS 2006 103 14925-14930.
17. Li JY, Baek KH, Bedi B, Adam J, Yang X, Weitzman M & Pacifici R. CD40L mediated T cell activation is required for estrogen deficiency to induce bone loss. Proceeding of the 31st Annual Meeting of the American Society for Bone and Mineral Research Denver, CO, Journal of Bone and Mineral Research 2009 24 S64.
18. Pacifici R. Immune system, FSH and regulation of bone mass. Proceeding of the 10st Annual Meeting of the Società Italiana dell'Osteoporosi del Metabolismo Minerale e delle Malattie dello Scheletro, Torino, Clinical Cases in Mineral and Bone Metabolism 2009 6 S32.
19. Palomba S, Numis FG, Mossetti G, Rendina D, Vuotto P, Russo T, Zullo F, Nappi C & Nunziata V. Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes. Clinical Endocrinology 2003 58 365-371.
20. Palomba S, Numis FG, Mossetti G, Rendina D, Vuotto P, Russo T, Zullo F, Nappi C & Nunziata V. Raloxifene administration in postmenopausal women with osteoporosis: effect of different Bsm I vitamin D receptor genotypes. Human Reproduction 2003 18 192-198. (Pubitemid 36138876)
21. Osteoporosis Prevention, Diagnosis, and Therapy Consensus Statement 2000. Journal of the American Medical Association 2001 285 785-795.
22. Sudo S, Kudo M, Wada S, Sato O, Hsueh AJ & Fujimoto S. Genetic and functional analyses of polymorphisms in the human FSH receptor gene. Molecular Human Reproduction 2002 8 893-899. (Pubitemid 35174921)
23. Gromoll J & Simoni M. Genetic complexity of FSH receptor function. Trends in Endocrinology and Metabolism 2005 16 368-373. (Pubitemid 41338742)
24. Rivadeneira F, Styrkársdottir U, Estrada K, Halldórsson BV, Hsu YH, Richards JB, Zillikens MC, Kavvoura FK, Amin N, Aulchenko YS, Cupples LA, Deloukas P, Demissie S, Grundberg E, Hofman A, Kong A, Karasik D, van Meurs JB, Oostra B, Pastinen T, Pols HA, Sigurdsson G, Soranzo N, Thorleifsson G, Thorsteinsdottir U, Williams FM, Wilson SG, Zhou Y, Ralston SH, van Duijn CM, Spector T, Kiel DP, Stefansson K, Ioannidis JP & Uitterlinden AG. Genetic Factors for Osteoporosis (GEFOS) Consortium. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nature Genetics 2009 41 1199-1206.
25. Ferrari S. Human genetics of osteoporosis. Best Practice & Research. Clinical Endocrinology & Metabolism 2008 2 723-735.
26. Eisman JA. Genetics of osteoporosis. Endocrine Reviews 1999 20 788-804.
27. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. Journal of Clinical Investigation 2005 115 3318-3325.
28. Demissie S, Dupuis J, Cupples LA, Beck TJ, Kiel DP & Karasik D. Proximal hip geometry is linked to several chromosomal regions: genome-wide linkage results from the Framingham Osteoporosis Study. Bone 2007 40 743-750. (Pubitemid 46187216)
29. Niu T, Chen C,Cordell H, Yang J, Wang B, Wang Z, Fang Z, Schork NJ, Rosen CJ & Xu X. A genome-wide scan for loci linked to forearm bone mineral density. Human Genetics 1999 104 226-233. (Pubitemid 29182601)
30. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, Jonsdottir T, Saemundsdottir J, Center JR, Nguyen TV, Bagger Y, Gulcher JR, Eisman JA, Christiansen C, Sigurdsson G, Kong A, Thorsteinsdottir U & Stefansson K. Multiple genetic loci for bone mineral density and fractures. New England Journal of Medicine 2008 358 2355-2365.
31. Caldwell JD & Jirikowski GF. Sex hormone binding globulin and aging. Hormone and Metabolic Research 2009 41 173-182.
32. Meduri G, Bachelot A, Cocca MP, Vasseur C, Rodien P, Kuttenn F, Touraine P & Misrahi M. Molecular pathology of the FSH receptor: new insights into FSH physiology. Molecular and Cellular Endocrinology 2008 282 130-142.
33. Danilovich N & Sairam MR. Targeting gonadotropin receptor genes: reproductive biology, aging, and related health implications. Endocrine 2005 26 219-226.
34. Perez Mayorga M, Gromoll J, Behre HM, Gassner C, Nieschlag E & Simoni M. Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. Journal of Clinical Endocrinology and Metabolism 2000 85 3365-3369.
35. de Castro F, Ruiz R, Montoro L, Pérez-Hernández D, Sánchez-Casas Padilla E, Real LM & Ruiz A. Role of follicle-stimulating hormone receptor Ser680Asn polymorphism in the efficacy of follicle-stimulating hormone. Fertility and Sterility 2003 80 571-576.
36. de Castro F, Morón FJ, Montoro L, Galán JJ, Hernández DP, Padilla ES, Ramírez-Lorca R, Real LM & Ruiz A. Human controlled ovarian hyperstimulation outcome is a polygenic trait. Pharmacogenetics 2004 14 285-293.
37. Behre HM, Greb RR, Mempel A, Sonntag B, Kiesel L, Kaltwasser P, Seliger E, Röpke F, Gromoll J, Nieschlag E & Simoni M. Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation. Pharmacogenetics and Genomics 2005 15 451-456.
38. Krishnamurthy H, Kishi H, Shi M, Galet C, Bhaskaran RS, Hirakawa T & Ascoli M. Postendocytotic trafficking of the follicle-stimulating hormone (FSH)-FSH receptor complex. Molecular Endocrinology 2003 17 2162-2176. (Pubitemid 37352529)
39. El Maghraoui A & Roux C. DXA scanning in clinical practice. Quarterly Journal of Medicine 2008 101 605-617.
40. El Maghraoui A, Mouinga Abayi DA, Ghozlani I, Mounach A, Nouijai A, Ghazi M, Achemlal L & Bezza A. Prevalence and risk factors of discordance in diagnosis of osteoporosis using spine and hip bone densitometry. Annals of the Rheumatic Diseases 2007 66 271-272. (Pubitemid 46226070)
41. Blank RD, Malone DG, Christian RC, Vallarta-Ast NL, Krueger DC, Drezner MK, Binkley NC & Hansen KE. Patient variables impact lumbar spine dual energy X-ray absorptiometry precision. Osteoporosis International 2006 17 768-774.